JP2019512485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512485A5 JP2019512485A5 JP2018547307A JP2018547307A JP2019512485A5 JP 2019512485 A5 JP2019512485 A5 JP 2019512485A5 JP 2018547307 A JP2018547307 A JP 2018547307A JP 2018547307 A JP2018547307 A JP 2018547307A JP 2019512485 A5 JP2019512485 A5 JP 2019512485A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 40
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000003536 tetrazoles Chemical class 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- -1 hydroxy, amino Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000004292 cyclic ethers Chemical group 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305392P | 2016-03-08 | 2016-03-08 | |
| US62/305,392 | 2016-03-08 | ||
| PCT/IB2017/051338 WO2017153919A1 (en) | 2016-03-08 | 2017-03-07 | Tricyclic compounds useful to treat orthomyxovirus infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512485A JP2019512485A (ja) | 2019-05-16 |
| JP2019512485A5 true JP2019512485A5 (enExample) | 2020-05-28 |
| JP6918819B2 JP6918819B2 (ja) | 2021-08-11 |
Family
ID=58347733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547307A Active JP6918819B2 (ja) | 2016-03-08 | 2017-03-07 | オルトミクソウイルス感染の処置に有用な三環式化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10858366B2 (enExample) |
| EP (1) | EP3426656B1 (enExample) |
| JP (1) | JP6918819B2 (enExample) |
| CN (1) | CN108699059B (enExample) |
| ES (1) | ES2881776T3 (enExample) |
| WO (1) | WO2017153919A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4219508B1 (en) | 2015-04-28 | 2024-06-05 | Shionogi & Co., Ltd | Substituted polycyclic pyridone derivative and prodrug thereof |
| CR20180356A (es) | 2015-12-15 | 2018-08-22 | Shionogi & Co | Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza |
| CN109069488B (zh) | 2016-03-07 | 2021-09-07 | 英安塔制药有限公司 | 乙型肝炎抗病毒剂 |
| WO2017153919A1 (en) * | 2016-03-08 | 2017-09-14 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| NZ791086A (en) | 2016-08-10 | 2025-08-29 | Shionogi & Co | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| MY203207A (en) | 2018-02-28 | 2024-06-14 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
| US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN111410661B (zh) * | 2019-01-04 | 2023-05-05 | 周雨恬 | 帽依赖性内切核酸酶抑制剂及其用途 |
| CN109912624B (zh) * | 2019-04-11 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种巴洛沙韦酯关键母核中间体的合成方法 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| DE15187654T1 (de) | 2001-08-10 | 2016-12-01 | Shionogi & Co., Ltd | Antivirales Mittel |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) * | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| FR2901795A1 (fr) * | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| MX2011004636A (es) | 2008-10-31 | 2011-06-20 | Shionogi & Co | Cefarosporinas que tienen un grupo catecol. |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| EP2412708A4 (en) * | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
| RS57244B1 (sr) * | 2009-06-15 | 2018-07-31 | Shionogi & Co | Supstituisani policiklički derivati karbamoilpiridona |
| WO2011123678A2 (en) * | 2010-03-31 | 2011-10-06 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| RS57490B1 (sr) | 2010-09-24 | 2018-10-31 | Shionogi & Co | Supstituisani prolek derivata policikličnog karbamoil piridona |
| WO2012151567A1 (en) * | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| KR20140090197A (ko) | 2011-10-12 | 2014-07-16 | 시오노기세야쿠 가부시키가이샤 | 인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체 |
| ES2604766T3 (es) | 2012-09-20 | 2017-03-09 | Celltrion, Inc. | Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo |
| AR094378A1 (es) * | 2013-01-08 | 2015-07-29 | Savira Pharmaceuticals Gmbh | Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral |
| NZ716822A (en) | 2013-08-21 | 2017-10-27 | Alios Biopharma Inc | Antiviral compounds |
| WO2015038665A1 (en) | 2013-09-11 | 2015-03-19 | University Of Southern California | A composition of stem cells having highly expressed fas ligand |
| KR102286860B1 (ko) | 2013-09-12 | 2021-08-05 | 얀센 바이오파마, 인코퍼레이트. | 피리다지논 화합물 및 이의 용도 |
| KR102323515B1 (ko) * | 2013-09-12 | 2021-11-05 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| CA2953862A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| MX383931B (es) | 2015-03-11 | 2025-03-14 | Janssen Biopharma Inc | Compuestos de aza-piridona y usos de estos. |
| WO2017153919A1 (en) | 2016-03-08 | 2017-09-14 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| NZ791086A (en) | 2016-08-10 | 2025-08-29 | Shionogi & Co | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| KR102477187B1 (ko) | 2018-01-17 | 2022-12-12 | 장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드 | 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 |
| MY203207A (en) | 2018-02-28 | 2024-06-14 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
-
2017
- 2017-03-07 WO PCT/IB2017/051338 patent/WO2017153919A1/en not_active Ceased
- 2017-03-07 ES ES17711349T patent/ES2881776T3/es active Active
- 2017-03-07 CN CN201780015673.6A patent/CN108699059B/zh active Active
- 2017-03-07 US US16/083,089 patent/US10858366B2/en active Active
- 2017-03-07 JP JP2018547307A patent/JP6918819B2/ja active Active
- 2017-03-07 EP EP17711349.5A patent/EP3426656B1/en active Active
-
2020
- 2020-07-20 US US16/933,000 patent/US11453677B2/en active Active